Stephens Inc. AR Buys Shares of 85,222 Enovis Co. (NYSE:ENOV)

Stephens Inc. AR bought a new stake in shares of Enovis Co. (NYSE:ENOV - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 85,222 shares of the company's stock, valued at approximately $3,740,000. Stephens Inc. AR owned approximately 0.15% of Enovis at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. UMB Bank n.a. boosted its stake in Enovis by 128.2% during the fourth quarter. UMB Bank n.a. now owns 778 shares of the company's stock worth $34,000 after acquiring an additional 437 shares in the last quarter. Pinnacle Bancorp Inc. boosted its stake in Enovis by 54.5% during the fourth quarter. Pinnacle Bancorp Inc. now owns 850 shares of the company's stock worth $37,000 after acquiring an additional 300 shares in the last quarter. DekaBank Deutsche Girozentrale bought a new stake in Enovis during the third quarter worth about $55,000. FMR LLC boosted its stake in Enovis by 20.5% during the third quarter. FMR LLC now owns 2,840 shares of the company's stock worth $122,000 after acquiring an additional 484 shares in the last quarter. Finally, Heritage Family Offices LLP purchased a new position in Enovis in the third quarter worth about $206,000. Institutional investors own 98.45% of the company's stock.

Enovis Stock Up 0.4 %

Enovis stock traded up $0.18 during trading hours on Friday, hitting $43.89. The stock had a trading volume of 391,660 shares, compared to its average volume of 1,022,775. The company has a quick ratio of 1.12, a current ratio of 2.27 and a debt-to-equity ratio of 0.40. The stock's 50-day moving average price is $45.37 and its 200-day moving average price is $44.40. Enovis Co. has a 12-month low of $38.27 and a 12-month high of $65.03. The stock has a market capitalization of $2.50 billion, a P/E ratio of -20.04 and a beta of 1.94.

Wall Street Analysts Forecast Growth

Separately, Needham & Company LLC reaffirmed a "buy" rating and issued a $65.00 target price on shares of Enovis in a report on Thursday, November 7th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $64.83.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.